SC
PCRX icon

Sierra Capital’s Pacira BioSciences PCRX Stock Holding History

Sierra Capital’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$317K Hold
12,500
– – 0.03% 193
2026
Q1 		$283K Hold
12,500
– – 0.03% 194
2025
Q4 		$324K Hold
12,500
– – 0.03% 174
2025
Q3 		$322K Hold
12,500
– – 0.04% 187
2025
Q2 		$299K Buy
+12,500
New +$315K 0.03% 188

Other funds holding PCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DPCM
Doma Perpetual Capital Management Miami, Florida $431M AUM 13.21% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Sierra Capital's PCRX Position: Q2 2026 in Review

Sierra Capital held its Pacira BioSciences (PCRX) position steady in Q2 2026 at 12,500 shares worth $317K. The position accounts for 0.03% of the portfolio, ranked #193.

Sierra Capital first reported a position in PCRX in Q2 2025 and has held it in 5 quarters since. The position peaked at $324K in Q4 2025. 254 funds tracked by Wall St. Rank hold PCRX as of Q2 2026.

  • Sierra Capital held 12,500 shares of Pacira BioSciences worth $317K as of Q2 2026.
  • Sierra Capital left its Pacira BioSciences share count unchanged in Q2 2026.
  • Pacira BioSciences made up 0.03% of Sierra Capital's portfolio in Q2 2026, its #193 holding.
  • Sierra Capital first reported a position in Pacira BioSciences in Q2 2025 and has held it in 5 quarters since.
  • Sierra Capital's Pacira BioSciences position peaked at $324K in Q4 2025.
  • 254 funds tracked by Wall St. Rank held Pacira BioSciences as of Q2 2026.

Based on Sierra Capital's 13F filing for Q2 2026, filed 14 Aug 2026.